Skip to content
JoelGalvan

JoelGalvan

View Video Stories
  • Home
  • Business
  • Culture
  • Sports
  • Home
  • Business
  • Culture
  • Sports
© https://joelgalvan.site/-All rights reserved. Theme Blognest designed by WPInterface.
  • Home
  • Pharmaceuticals

Tag: Pharmaceuticals

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today
Posted in Business

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today

Estimated read time 2 min read
Posted on June 6, 2025
by Joelgalvan

We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going…

Learn More Leave a Comment on Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today
Biodexa Pharmaceuticals sees cash runway into 1Q26
Posted in Business

Biodexa Pharmaceuticals sees cash runway into 1Q26

Estimated read time 2 min read
Posted on June 1, 2025
by Joelgalvan

As of May 29, 2025, the Company had access to the following cash resources: Cash at bank $5.7M; Cash in…

Learn More Leave a Comment on Biodexa Pharmaceuticals sees cash runway into 1Q26
Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target
Posted in Business

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

Estimated read time 2 min read
Posted on May 31, 2025
by Joelgalvan

On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy…

Learn More Leave a Comment on Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
Posted in Business

ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials

Estimated read time 2 min read
Posted on May 30, 2025
by Joelgalvan

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) has unveiled promising early results from its Phase 1b trial of ORIC-944, a novel PRC2 inhibitor,…

Learn More Leave a Comment on ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut
Posted in Business

Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut

Estimated read time 2 min read
Posted on May 21, 2025
by Joelgalvan

Accretion Pharmaceuticals, a Gujarat-based pharma manufacturer, concluded its Rs 29.75 crore SME IPO on May 16. The issue, priced between…

Learn More Leave a Comment on Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut
Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
Posted in Business

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

Estimated read time 1 min read
Posted on May 17, 2025
by Joelgalvan

Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on…

Learn More Leave a Comment on Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?
Posted in Business

Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?

Estimated read time 5 min read
Posted on May 14, 2025
by Joelgalvan

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are…

Learn More Leave a Comment on Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?
GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
Posted in Business

GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion

Estimated read time 2 min read
Posted on May 14, 2025
by Joelgalvan

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm…

Learn More Leave a Comment on GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
Accretion Pharmaceuticals IPO opens for subscription: Price band, GMP among key details to know
Posted in Business

Accretion Pharmaceuticals IPO opens for subscription: Price band, GMP among key details to know

Estimated read time 2 min read
Posted on May 14, 2025
by Joelgalvan

Accretion Pharmaceuticals has opened its initial public offering (IPO) for subscription today, May 14. The IPO, which is set to…

Learn More Leave a Comment on Accretion Pharmaceuticals IPO opens for subscription: Price band, GMP among key details to know

Recent Posts

  • Oilers’ hard-fought Game 2 comeback upended in double OT
  • Carlos Yulo wins fourth straight floor gold at Asian Championships
  • Delhi Airport to cancel 114 daily flights for runway upgrade from June 15 to Sept 15; check details
  • Stock Futures Rise as Investors Weigh Up Trump-Musk Feud Ahead of Jobs Report
  • Stars, snubs, surprises: What to make of USMNT’s Gold Cup roster

Recent Comments

No comments to show.

Archives

  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025

Categories

  • Business
  • Culture
  • Sports
© https://joelgalvan.site/-All rights reserved. Theme Blognest designed by WPInterface.